Astrazeneca Pharma India falls; Sebi says exchanges to monitor delisting

Shares in Astrazeneca Pharma India Ltd fell 3 percent after the SEBI on Tuesday

RELATED ARTICLES

said stock exchanges will closely monitor the company's delisting process and promptly report any aberrations.

"The promoters of M/s Astrazeneca Pharma India Ltd. shall finally purchase shares from public shareholders in the delisting offer only after seeking approval of the Bombay Stock Exchange Limited and National Stock Exchange Limited," added the Securities and Exchange Board of India in an order.

The regulator also said it came across certain reports that the offer for sale (OFS) of the shares of Astrazeneca Pharma India Ltd carried out by its promoter AstraZeneca Pharmaceuticals AB Sweden on May 26, 2013 was a deliberate attempt to subsequently get the shares of the Indian unit delisted at ease.

It was also reported that more than 94 percent of total shares offered through OFS had been subscribed by six foreign institutional investors including DB International Asia Ltd, Suffolk (Mauritius), Morgan Stanley Asia (Singapore) PTE, BNP Paribas Arbitrage, Manfield (Mauritius) Ltd and Merrill Lynch Capital Markets Espana S.A. SVB.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • But what’s the big deal about Modi’s first hundred days?

    That Indians believe more in symbolism than substance is a fact that is well acknowledged and chronicled.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schöttli

West Asia turmoil worries east Asia

From Beijing to Jakarta, from Manila to Tokyo, east Asian ...

Purnendu Ghosh

Memory is a collage of the old and new

We are all fitted with pressure valves. Some of us ...

Shona Adhikari

The enduring legacy of <em>The Last Supper</em>

This week’s column features a work of art that is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture